Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832453 | 0.82 | PARP1 (1.00) | PARP1PARP2HTTLMNA | |
| SCHEMBL833312 | 0.81 | PARP1 (1.00) | PARP1PARP2HTTLMNA | |
| SCHEMBL834674 | 0.76 | PARP1 (0.67) | PARP1PARP2HTTLMNA | |
| SCHEMBL4196231 | 0.74 | PARP1 (0.59) | PARP1POLB | |
| SCHEMBL6123445 | 0.74 | PARP1 (0.71) | PARP1PARP2HTTLMNA | |
| Hydrochloric Acid SCHEMBL4195897 | 0.74 | PARP1 (0.58) | PARP1POLB | |
| SCHEMBL834344 | 0.72 | PARP1 (1.00) | PARP1PARP2HTTLMNA | |
| SCHEMBL1867231 | 0.72 | PARP1 (0.76) | PARP1PARP2HTTLMNA | |
| SCHEMBL15662435 | 0.72 | PARP1 (1.00) | PARP1PARP2HTTLMNA | |
| SCHEMBL15661740 | 0.71 | PARP1 (1.00) | PARP1PARP2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143284-B2 | 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, | ABBOTT LABORATORIES (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBVIE INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108659-A1 | POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885HTT 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.